Axogen Inc (AXGN) Stock Price, Quote & News

Company Profile

Axogen, Inc., together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral...

Industry: Medical Devices

Sector: Healthcare

Phone: 386 462 6800

Fax: 386 462 6801

Website: www.axogeninc.com

Address:

13631 Progress Boulevard, Suite 400, Alachua, United States

dustin1101 Jan. 13 at 3:06 PM

$AXGN Added a few hundred. Just an opportunity here.

0 · Reply

KatherinePinto269 Jan. 12 at 5:33 PM

$CRK $AXGN Energy meets medtech

0 · Reply

dustin1101 Jan. 12 at 4:26 PM

$AXGN Jeffries raises target $36-$40 and still dummies hitting bid with low vol sells.

0 · Reply

dustin1101 Jan. 12 at 2:36 PM

$AXGN Raised guidance (again) and people are selling? 😂

0 · Reply

DARKP00L Jan. 12 at 12:35 PM

$AXGN 07:15 on Jan. 12 2026 Axogen Raises FY2025 Sales Guidance from $222.800M to $225.200M vs $223.339M Est #tradeideas

0 · Reply

DARKP00L Jan. 12 at 12:17 PM

$AXGN 07:15 on Jan. 12 2026 Axogen Sees Q4 Sales $59.900M vs $58.000M Est #tradeideas

0 · Reply

dustin1101 Jan. 9 at 5:31 PM

$AXGN So close to sending.. though this typically doesn’t have strong Fridays. Maybe this one is different.

0 · Reply

dustin1101 Jan. 8 at 6:48 PM

$AXGN fishy drop on no volume.. possible bear trap

1 · Reply

DougAfter60 Jan. 7 at 8:04 PM

$AXGN nice turnaround

0 · Reply

dustin1101 Jan. 7 at 3:31 PM

$AXGN Well this is one way to hookwink the shorts! Still 2.5M on the last report.. You know they’re all sitting on a losing position now.

0 · Reply

Axogen, Inc. Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2025

Dec 3, 2025, 8:01 PM EST - 5 weeks ago

Axogen Announces FDA Approval of Biologics License Application for AVANCE® (acellular nerve allograft–arwx)

Dec 3, 2025, 6:53 PM EST - 5 weeks ago

FDA approves Axogen's nerve repair graft

Dec 1, 2025, 12:33 PM EST - 6 weeks ago

Avance Nerve Graft FDA Verdict Approaches, Why Investors Are Watching Axogen

Nov 5, 2025, 2:19 PM EST - 2 months ago

Wasatch Micro Cap Value Fund Q3 2025 Contributors And Detractors

BELFB LMB PMTS WLDN

Oct 29, 2025, 2:26 PM EDT - 2 months ago

Axogen, Inc. (AXGN) Q3 2025 Earnings Call Transcript

Oct 29, 2025, 7:00 AM EDT - 2 months ago

Axogen, Inc. Reports Third Quarter 2025 Financial Results

Oct 1, 2025, 12:30 PM EDT - 3 months ago

Axogen, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – AXGN

Oct 1, 2025, 10:50 AM EDT - 3 months ago

AXGN Investors Have Opportunity to Join Axogen, Inc. Fraud Investigation with the Schall Law Firm

Aug 25, 2025, 6:40 AM EDT - 5 months ago

Axogen Provides Update on FDA Review Timeline for Avance Nerve Graft

Aug 12, 2025, 5:17 AM EDT - 5 months ago

Axogen: Broad Range Of Outcomes Still Present, Opting To Remain Sidelined

Aug 5, 2025, 1:15 PM EDT - 5 months ago

Axogen, Inc. (AXGN) Q2 2025 Earnings Call Transcript

Jul 29, 2025, 4:10 PM EDT - 6 months ago

Axogen, Inc. to participate at the Canaccord Genuity 45th Annual Growth Conference

Jul 22, 2025, 4:05 PM EDT - 6 months ago

Axogen, Inc. to report 2025 second quarter financial results on August 5, 2025

May 28, 2025, 8:00 AM EDT - 8 months ago

Axogen, Inc to Participate at Goldman Sachs Global Healthcare Conference

May 9, 2025, 3:21 PM EDT - 8 months ago

Axogen, Inc. (AXGN) Q1 2025 Earnings Call Transcript

May 8, 2025, 7:05 AM EDT - 8 months ago

Axogen, Inc. Reports 2025 First Quarter Financial Results

Apr 24, 2025, 8:04 AM EDT - 9 months ago

Axogen, Inc. to report 2025 first quarter financial results on May 8, 2025

Feb 25, 2025, 1:58 PM EST - 11 months ago

Axogen, Inc. (AXGN) Q4 2024 Earnings Call Transcript

Feb 25, 2025, 7:10 AM EST - 11 months ago

Axogen, Inc. To Host Analyst & Investor Day on March 4th

Feb 11, 2025, 4:58 PM EST - 1 year ago

Axogen, Inc. to report 2024 fourth quarter and full year financial results on February 25, 2025

Jan 10, 2025, 5:00 PM EST - 1 year ago

Axogen Announces New VP of Operations and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Jan 6, 2025, 8:01 PM EST - 1 year ago

Axogen: Well Placed To Capitalize Growth At Higher Multiples

Nov 9, 2024, 9:53 AM EST - 1 year ago

Axogen, Inc (AXGN) Q3 2024 Earnings Call Transcript

Sep 6, 2024, 7:00 AM EDT - 1 year ago

Axogen Completes Submission of Biologics License Application to U.S. Food and Drug Administration for Avance Nerve Graft®

Aug 8, 2024, 2:10 PM EDT - 1 year ago

Apple, Inc. (AXGN) Q2 2024 Earnings Call Transcript

Aug 8, 2024, 7:05 AM EDT - 1 year ago

Axogen, Inc. Announces New Leadership Appointments

Jul 23, 2024, 7:00 AM EDT - 1 year ago

Axogen, Inc. to Report Second Quarter 2024 Financial Results and Host Conference Call on August 8, 2024

Jul 1, 2024, 7:00 AM EDT - 1 year ago

Company Reports Inducement Grants to Non-Executive New Employee Under Nasdaq Listing Rule 5635(C)(4)

Jun 24, 2024, 7:00 AM EDT - 1 year ago

Axogen, Inc Announces Full Launch of Avive+ Soft Tissue Matrix™

May 28, 2024, 4:30 PM EDT - 1 year ago

Axogen Processing Center (APC) Celebrates its Opening with Ohio Leaders in Vandalia

May 5, 2024, 1:21 AM EDT - 1 year ago

AxoGen, Inc. (AXGN) Q1 2024 Earnings Call Transcript

May 2, 2024, 7:00 AM EDT - 1 year ago

Axogen, Inc Reports First Quarter 2024 Financial Results

Apr 29, 2024, 4:50 PM EDT - 1 year ago

Axogen Announces First Surgical Implants of Avive+ Soft Tissue Matrix™

Apr 16, 2024, 7:00 AM EDT - 1 year ago

Axogen, Inc. to Report First Quarter 2024 Financial Results and Host Conference Call on May 2, 2024

Mar 5, 2024, 11:03 AM EST - 2 years ago

AxoGen, Inc. (AXGN) Q4 2023 Earnings Call Transcript

Mar 5, 2024, 7:00 AM EST - 2 years ago

Axogen, Inc Reports 2023 Fourth Quarter and Full-Year Financial Results

Feb 13, 2024, 4:30 PM EST - 2 years ago

Axogen, Inc. to Report 2023 Fourth Quarter and Full-Year Financial Results on March 5, 2024

Feb 2, 2024, 4:15 PM EST - 2 years ago

Company Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Jan 18, 2024, 5:00 PM EST - 2 years ago

Axogen, Inc. Announces Positive Topline Results from REPOSE, a Prospective, Randomized Clinical Trial of Axoguard Nerve Cap

Jan 4, 2024, 4:45 PM EST - 2 years ago

Axogen Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2023

Jan 4, 2024, 4:40 PM EST - 2 years ago

Axogen Announces Plan for Leadership Transition with CEO Karen Zaderej to Retire from Company by January 2025

Jan 4, 2024, 4:35 PM EST - 2 years ago

Axogen Announces Promotions on Research and Development Team

Dec 26, 2023, 4:15 PM EST - 2 years ago

Axogen, Inc. Appoints Kathy Weiler to its Board of Directors

Dec 6, 2023, 7:00 AM EST - 2 years ago

Axogen Announces Transition of Finance Team Leadership

Dec 1, 2023, 5:00 PM EST - 2 years ago

Company Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Nov 7, 2023, 9:49 AM EST - 2 years ago

AxoGen, Inc. (AXGN) Q3 2023 Earnings Call Transcript

Nov 7, 2023, 7:00 AM EST - 2 years ago

Axogen, Inc. Reports 2023 Third Quarter Financial Results

dustin1101 Jan. 13 at 3:06 PM

$AXGN Added a few hundred. Just an opportunity here.

0 · Reply

KatherinePinto269 Jan. 12 at 5:33 PM

$CRK $AXGN Energy meets medtech

0 · Reply

dustin1101 Jan. 12 at 4:26 PM

$AXGN Jeffries raises target $36-$40 and still dummies hitting bid with low vol sells.

0 · Reply

dustin1101 Jan. 12 at 2:36 PM

$AXGN Raised guidance (again) and people are selling? 😂

0 · Reply

DARKP00L Jan. 12 at 12:35 PM

$AXGN 07:15 on Jan. 12 2026 Axogen Raises FY2025 Sales Guidance from $222.800M to $225.200M vs $223.339M Est #tradeideas

0 · Reply

DARKP00L Jan. 12 at 12:17 PM

$AXGN 07:15 on Jan. 12 2026 Axogen Sees Q4 Sales $59.900M vs $58.000M Est #tradeideas

0 · Reply

dustin1101 Jan. 9 at 5:31 PM

$AXGN So close to sending.. though this typically doesn’t have strong Fridays. Maybe this one is different.

0 · Reply

dustin1101 Jan. 8 at 6:48 PM

$AXGN fishy drop on no volume.. possible bear trap

1 · Reply

DougAfter60 Jan. 7 at 8:04 PM

$AXGN nice turnaround

0 · Reply

dustin1101 Jan. 7 at 3:31 PM

$AXGN Well this is one way to hookwink the shorts! Still 2.5M on the last report.. You know they’re all sitting on a losing position now.

0 · Reply

dustin1101 Jan. 6 at 3:11 PM

$AXGN I’d be surprised if big pharma wasn’t sniffing around here. They’ll want the biologic that becomes the new standard of care and the tech behind it that can be used for far more applications. It’s a matter of when, not if, IMO. Break $34 and we’re off to new highs.

0 · Reply

garygb Jan. 3 at 8:13 PM

$AXGN Oversold

0 · Reply

dustin1101 Jan. 2 at 6:33 PM

$AXGN Let’s see if recent history repeats.

0 · Reply

dustin1101 Jan. 2 at 2:57 PM

$AXGN Added some just under $32. Don’t think this dip lasts long.

2 · Reply

TalkMarkets Dec. 31 at 4:36 AM

This Quiet S&P 500 Rally Is Sending A Clear Message (Most People Are Missing It) $SPX $XPEL $NUTX $AXGN https://talkmarkets.com/content/stocks--equities/this-quiet-sp-500-rally-is-sending-a-clear-message-most-people-are-missing-it?post=547437

0 · Reply

dustin1101 Dec. 30 at 5:50 PM

$AXGN Nice consolidation now for almost a month. Floor is rising as the sellers get chipped away up to the 52wk high. From there I think we see a $4-6 move into the next range. Trend is your friend.

0 · Reply

dustin1101 Dec. 29 at 8:26 PM

$AXGN Volume alert. News?

0 · Reply

kgnfdeagle Dec. 26 at 6:10 PM

$AXGN Entered again at$32.25 ; 500 shares ; looks to run from here.

0 · Reply

dustin1101 Dec. 23 at 9:09 PM

$AXGN Next stop $38+ IMO. What a beast. $45 right now and they can have all my shares 😉.

0 · Reply

freeindeed Dec. 22 at 9:12 PM

$AXGN Here's a lump of coal for all you shorts. Sorry, you'll have to divide it.💩 Merry Christmas longs!

1 · Reply

isaacwilliams33 Dec. 17 at 8:32 PM

$AXGN ge

0 · Reply

dustin1101 Dec. 17 at 7:21 PM

$AXGN big $ deciding it’s not worth waiting any longer. In the face of a red mkt. I added some early today and on the first dip. Back to just over 10K shares strong.

0 · Reply

Market Cap	1.46B
Revenue (ttm)	187.34M
Net Income (ttm)	-9.96M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	197.12
Profit Margin	-5.32%
Debt to Equity Ratio	0.40

Volume	155,530
Avg Vol	872,450
Day's Range	N/A - N/A
Shares Out	46.12M
Stochastic %K	14%
Beta	1.00
Analysts	Strong Sell
Price Target	$36.55